Cover Image
市場調查報告書

Boehringer Ingelheim GmbH:產品平台分析

Boehringer Ingelheim GmbH - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240911
出版日期 內容資訊 英文 186 Pages
訂單完成後即時交付
價格
Back to Top
Boehringer Ingelheim GmbH:產品平台分析 Boehringer Ingelheim GmbH - Product Pipeline Review - 2016
出版日期: 2016年05月11日 內容資訊: 英文 186 Pages
簡介

Boehringer Ingelheim GmbH是針對皮膚科及血栓症的醫藥品進行藥物研發,開發,製造及商品化的獨立型醫藥品研究企業。

本報告提供Boehringer Ingelheim GmbH的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Boehringer Ingelheim GmbH的基本資料

Boehringer Ingelheim GmbH概要

  • 主要資訊
  • 企業資料

Boehringer Ingelheim GmbH:研究開發概要

  • 主要的治療範圍

Boehringer Ingelheim GmbH:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

Boehringer Ingelheim GmbH:開發中產品概況

  • 後期開發中產品
  • 臨床實驗階段的開發中產品
  • 初期階段的開發中產品

Boehringer Ingelheim GmbH:藥物簡介

Boehringer Ingelheim GmbH:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Boehringer Ingelheim GmbH:最近的開發平台趨勢

Boehringer Ingelheim GmbH:暫停中的計劃

Boehringer Ingelheim GmbH:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Boehringer Ingelheim GmbH:企業發表

Boehringer Ingelheim GmbH:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08045CDB

Summary

Global Markets Direct's, 'Boehringer Ingelheim GmbH - Product Pipeline Review - 2016', provides an overview of the Boehringer Ingelheim GmbH's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Boehringer Ingelheim GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Boehringer Ingelheim GmbH
  • The report provides overview of Boehringer Ingelheim GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Boehringer Ingelheim GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Boehringer Ingelheim GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Boehringer Ingelheim GmbH's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Boehringer Ingelheim GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Boehringer Ingelheim GmbH's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Boehringer Ingelheim GmbH Snapshot
    • Boehringer Ingelheim GmbH Overview
    • Key Information
    • Key Facts
  • Boehringer Ingelheim GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Boehringer Ingelheim GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Boehringer Ingelheim GmbH - Pipeline Products Glance
  • Boehringer Ingelheim GmbH - Late Stage Pipeline Products
  • Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products
  • Boehringer Ingelheim GmbH - Early Stage Pipeline Products
  • Boehringer Ingelheim GmbH - Drug Profiles
    • (empagliflozin + linagliptin)
    • (linagliptin + metformin hydrochloride ER)
    • (olodaterol hydrochloride + tiotropium bromide)
    • idarucizumab
    • (empagliflozin + metformin hydrochloride XR)
    • adalimumab biosimilar
    • afatinib dimaleate
    • bevacizumab biosimilar
    • empagliflozin
    • nintedanib
    • risankizumab
    • rituximab biosimilar
    • volasertib trihydrochloride
    • BI-1026706
    • BI-1361849
    • BI-144807
    • BI-409306
    • FX-125L
    • HM-61713
    • BI-836826
    • BI-836845
    • BI-836858
    • BI-1005273
    • BI-1060469
    • BI-113608
    • BI-416970
    • BI-425809
    • BI-443651
    • BI-655064
    • BI-655088
    • BI-655130
    • BI-685509
    • BI-836880
    • BI-836909
    • BI-853520
    • BI-860585
    • BI-894999
    • PXS-4728A
    • Small Molecule for Oncology
    • AR-116082
    • BI-113823
    • BI-1467335
    • BI-186908
    • BI-207524 Follow-Up
    • BI-703704
    • BI-882370
    • CNX-012
    • CNX-012570
    • linagliptin
    • Monoclonal Antibody for Ophthalmology
    • olcegepant
    • Small Molecule 2 for Oncology
    • Small Molecule 2 to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis
    • Small Molecule 3 for Oncology
    • Small Molecule for Respiratory Diseases
    • Small Molecule to Agonize Glucocorticoid Receptor for Inflammation
    • Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis
    • Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection
    • Small Molecules for Respiratory Disorders
    • Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection
    • Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy
    • Synthetic Peptide for CardioMetabolic Disease
    • Antibody for Oncology
    • BI-665915
    • Small Molecule for HIV
    • Small Molecule for HIV-1 Infection
    • Small Molecule to Agonize Glucocorticoid Receptor
    • Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders
    • Small Molecules for Oncology
    • Small Molecules for Schizophrenia
    • Small Molecules for Undisclosed Indication
    • Small Molecules to Inhibit K-Ras for Oncology
    • Small Molecules to Inhibit Kinases for Oncology
    • Synthetic Peptide to Agonize Glucagon and GLP-1 for Metabolic Disorders
  • Boehringer Ingelheim GmbH - Pipeline Analysis
    • Boehringer Ingelheim GmbH - Pipeline Products by Target
    • Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration
    • Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type
    • Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action
  • Boehringer Ingelheim GmbH - Recent Pipeline Updates
  • Boehringer Ingelheim GmbH - Dormant Projects
  • Boehringer Ingelheim GmbH - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Boehringer Ingelheim GmbH - Company Statement
  • Boehringer Ingelheim GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Boehringer Ingelheim GmbH, Key Information
  • Boehringer Ingelheim GmbH, Key Facts
  • Boehringer Ingelheim GmbH - Pipeline by Indication, 2016
  • Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016
  • Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016
  • Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016
  • Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016
  • Boehringer Ingelheim GmbH - Partnered Products/ Combination Treatment Modalities, 2016
  • Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2016
  • Boehringer Ingelheim GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Boehringer Ingelheim GmbH - Pre-Registration, 2016
  • Boehringer Ingelheim GmbH - Phase III, 2016
  • Boehringer Ingelheim GmbH - Phase II, 2016
  • Boehringer Ingelheim GmbH - Phase I, 2016
  • Boehringer Ingelheim GmbH - Preclinical, 2016
  • Boehringer Ingelheim GmbH - Discovery, 2016
  • Boehringer Ingelheim GmbH - Pipeline by Target, 2016
  • Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2016
  • Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016
  • Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action, 2016
  • Boehringer Ingelheim GmbH - Recent Pipeline Updates, 2016
  • Boehringer Ingelheim GmbH - Dormant Developmental Projects,2016
  • Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2016
  • Boehringer Ingelheim GmbH, Subsidiaries

List of Figures

  • Boehringer Ingelheim GmbH - Pipeline by Top 10 Indication, 2016
  • Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016
  • Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016
  • Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016
  • Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016
  • Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2016
  • Boehringer Ingelheim GmbH - Pipeline by Top 10 Target, 2016
  • Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2016
  • Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016
  • Boehringer Ingelheim GmbH - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top